FDA approves expanded Camzyos label for Bristol Myers Squibb to treat obstructive HCM in patients weighing 30 kg or more
Bitget2026/09/30 21:32- FDA cleared an expanded label for Bristol Myers Squibb’s Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy in adults.
- Decision adds pediatric patients weighing 30 kg or more, making Camzyos the only FDA-approved oHCM therapy for children.
- Approval backed by Phase 3 SCOUT-HCM data showing a 48 mmHg greater reduction in Valsalva LVOT gradient versus placebo at week 28.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pakistan stock index closed up 0.3%

ASML rises over 4% in pre-market trading

Exports Surpass $1 Trillion for the First Time! AI Chip Boom Makes South Korea the World's Fourth Largest Exporter
South Korea's annual exports have surpassed $1 trillion for the first time, ranking fourth globally, driven by the semiconductor boom. However, private consumption contracted in the third quarter, indicating that the benefits have not reached households.

Scallop wallet extension launches gas-free stablecoin transfers, supporting USDC, USDsui, and more
